INH1, a thiazolyl benzamide compound, is a cell-permeable Hec1/Nek2 mitotic pathway inhibitor I.

Treating cells with INH1 triggered reduction of kinetochore-bound Hec1 as well as global Nek2 protein level, consequently leading to metaphase chromosome misalignment, spindle aberrancy, and eventual cell death. INH1 effectively inhibited the proliferation of multiple human breast cancer cell lines in culture (GI(50), 10-21 micromol/L). Furthermore, treatment with INH1 retarded tumor growth in a nude mouse model bearing xenografts derived from the human breast cancer line MDA-MB-468, with no apparent side effects. This study suggests that the Hec1/Nek2 pathway may serve as a novel mitotic target for cancer intervention by small compounds.

(20S)-Protopanaxatriol

(beta)-Carotene

(E)-2-Decenoic acid

(gamma)-GT

(R)-(-)-Modafinic acid

(R)-Oxiracetam

(S)-(+)-Modafinic acid

(Z)-2-decenoic acid

10-Oxo Docetaxel

2-Thiouracil